Page 12 - Briefing Document News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ChemoCentryx, Inc. Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Deadline in Securities Fraud Class Action Lawsuit Kessler Topaz Meltzer & Check LLP Radnor, Pennsylvania, UNITED STATES RADNOR, Pa., May 10, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against ChemoCentryx, Inc. (NASDAQ: CCXI) (“ChemoCentryx”) on behalf of those who purchased or acq...

Share this article Share this article NEW YORK, May 11, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ChemoCentryx, Inc. ("ChemoCentryx" or "the Company") (NASDAQ: CCXI) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired ChemoCentryx securities between November 26, 2019 and May 3, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/ccxi.  This class action ...

NEW YORK, May 11, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI).  Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether ChemoCentryx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  - Advertisement - On May 4, 2021, the U.S. Food and Drug Administration ("FDA") released a "Briefing Document" concerning ChemoCent...

Share this article Share this article NEW YORK, May 11, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether ChemoCentryx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  On May 4, 2021, the U.S. Food and Drug Administration ("FDA") released a "Briefing Document" concerning Ch...

RADNOR, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action...